Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests that the interaction between CXXC5 and Dishevelled is a potential target for promoting hair regrowth and hair follicle formation, offering a new approach to treat hair loss.

This study found that inhibiting the interaction between CXXC5 and Dishevelled could stimulate hair regrowth in mouse models by enhancing WNT/β-catenin signaling, suggesting a potential therapeutic strategy for hair loss involving compounds that block this interaction, such as interfering short peptides.

This study identified CXXC5 as a key mediator of hair loss induced by PGD2 and DHT via suppression of the Wnt/β-catenin pathway, with implications for potential therapeutic targets.

This study found that KY19382, a small molecule activating the Wnt/β-catenin pathway, significantly improved wound healing by enhancing cell migration, increasing collagen and stem cell markers, and accelerating re-epithelialization and neo-epidermis formation in a murine model without causing significant cytotoxicity.

This study found that KY19382 can effectively promote hair regeneration and follicle neogenesis in mice and human hair models by activating Wnt/β-catenin signalling, suggesting potential use for alopecia treatment.

This study observed that the small molecules KY19382 and KY19334 inhibited cancerous traits in human cutaneous squamous cell carcinoma cells by suppressing the Wnt/β-catenin pathway, indicating their potential as treatments for cancers involving CDK1 overexpression and diseases related to CXXC5 accumulation.

In this study, KY19382 was observed to promote hair regeneration and de novo hair follicle formation in mice by activating Wnt/β-catenin signaling, suggesting its potential as a therapeutic for alopecia.

This review synthesizes recent research on how Wnt signaling regulates skin, hair follicle, and nail regeneration, highlighting its compartment-specific roles and discussing targeted strategies for treating conditions like alopecia, chronic wounds, and skin cancer.

This review discusses the mechanisms regulating wound-induced hair-follicle neogenesis and highlights potential treatments, like Wnt signaling activators, for enhancing this process in humans, yet reports no new clinical results.

In this review, researchers explored key mechanisms underlying androgenetic alopecia, revealing how hormonal, oxidative, inflammatory, and lipid dysregulation suppress hair growth pathways and suggesting new therapeutic targets such as DP2 antagonists and microbiome modulators.

This review explores emerging therapies for hair regrowth, highlighting two strategies: hair follicle neogenesis and Wnt/B-catenin pathway modulation, which show promise for treating alopecia by potentially offering more effective options than existing treatments.

This study found that the CXXC5 protein is overexpressed in diabetic foot ulcer tissues, suppressing wound healing, and that the small molecule KY19334 accelerated healing in diabetic mice by activating the Wnt/β-catenin pathway.

This study highlights emerging regenerative strategies, such as stem cell-derived therapies and machine learning tools, that may advance hair loss treatment beyond traditional methods by promoting follicle regeneration and offering personalized care.

In this study, an ammonia-free and PPD-free permanent hair dye was tested on 50 ethnically diverse females, showing no cases of contact dermatitis and significant improvements in hair shine, color, moisturization, porosity, and combability after two dyeing sessions.

This study reports that valproic acid is effective in treating absence seizures and shows improvement in other types of seizures, though about 20% of patients experienced adverse effects.

This observational study found that while 96.6% of patients using valproic acid showed the expected clinical response, over half experienced adverse reactions like weight gain, hair loss, and hepatotoxicity, highlighting the need for personalized treatment approaches to minimize these side effects.

This study found that valproic acid is effective in controlling absence seizures and can improve other seizure types, but 20% of patients experience mostly transient adverse reactions.

This case report describes a child developing pancreatitis directly linked to valproic acid therapy.

This article reviews the uses, mechanisms, and side effects of valproate in treating bipolar disorder, noting its first-line status for several manic conditions but also highlighting serious risks such as fetal abnormalities.

This study presents a case of a 24-year-old man who developed mild transaminitis and rhabdomyolysis within 24 hours of starting valproic acid for seizures, with symptom resolution following drug cessation.

This review compiles recent findings on the pharmacokinetics, pharmacodynamics, and pharmacogenomics of Valproate, highlighting potential new uses, benefits, and risks, but reports no new clinical results.

This study found that thrombocytopenia is a common side effect of valproic acid, affecting up to 54% of elderly patients, but it is under-investigated despite significant therapeutic consequences.

This study examined treatments for emesis in young Alexander disease patients, finding that 95% responded positively to valproic acid, which was more effective than anti-reflux medications or cyproheptadine, though some adverse effects require monitoring.

This study observed that while valproic acid treatment in children led to occasional mild clinical and laboratory side effects, no correlation with drug plasma levels was found.

This review highlights valproic acid's efficacy and tolerability as a first-line treatment for various seizure types in both adults and children, emphasizing its minimal neurological adverse effects compared to other antiepileptic drugs.

Low dose valproic acid treatment caused hair loss in a young patient.

This review found that valproic acid treatment significantly increases the risk of alopecia compared to other drugs, regardless of dose or treatment duration.

In this study, sodium valproate achieved complete seizure control in 82% of children as monotherapy, with higher plasma levels potentially linked to resistant cases.

This review discusses valproate-associated hair abnormalities, describing their common and benign nature, and outlines management strategies, though new clinical results are not provided.

This study found that venous blood ammonia levels, particularly in patients taking valproate combined with other antiepileptic drugs, were significantly elevated compared to those on valproate alone.